Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry

2016 ◽  
Vol 35 (3) ◽  
pp. 323-328 ◽  
Author(s):  
Kosei Matsue ◽  
Yuya Matsue ◽  
Kaoru Kumata ◽  
Yoshiaki Usui ◽  
Yasuhito Suehara ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Plasma Cell ◽  
Bone Marrow Aspirate ◽  
Cell Infiltration ◽  
Plasma Cell Infiltration ◽  
Bone Marrow Plasma

BONE MARROW PLASMA CELL INFILTRATION IN MULTIPLE MYELOMA

1984 ◽  
Vol 57 (2) ◽  
pp. 351-352 ◽  
Author(s):  
Aimery De Gramon ◽  
Oscar Benitez ◽  
Nicole Smadja ◽  
Philippe Brissaud ◽  
Agnés Sirinelli ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Plasma Cell ◽  
Cell Infiltration ◽  
Plasma Cell Infiltration ◽  
Bone Marrow Plasma

BONE MARROW PLASMA CELL INFILTRATION IN MULTIPLE MYELOMA

1984 ◽  
Vol 57 (2) ◽  
pp. 352-353 ◽  
Author(s):  
M. Cavo ◽  
M. Baccarani ◽  
M. Gobbi ◽  
A. Lipizer ◽  
S. Tura
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Plasma Cell ◽  
Cell Infiltration ◽  
Plasma Cell Infiltration ◽  
Bone Marrow Plasma

scholarly journals Relationship between Circulating BAFF Serum Levels with Proliferating Markers in Patients with Multiple Myeloma

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Michael G. Alexandrakis ◽  
Parascevi Roussou ◽  
Constantina A. Pappa ◽  
Ippokratis Messaritakis ◽  
Athina Xekalou ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Growth Factor ◽  
Plasma Cell ◽  
Serum Levels ◽  
Cell Infiltration ◽  
Ki 67 ◽  
Myeloma Cells ◽  
Plasma Cell Infiltration ◽  
Bone Marrow Plasma

In multiple myeloma, there are many factors influencing the growth of the malignant clone in direct and indirect manners. BAFF is a growth factor for myeloma cells. The aim of the study was to measure its circulating levels in 54 pretreatment patients, along with serum levels of other proliferation markers, such as interleukins-6, -10, and -15, CRP, and beta-2 microglobulin, as well as bone marrow plasma cell infiltration and expression of Ki-67 PI, in various stages of the disease and after effective treatment in 28 of them. Serum levels of the previously mentioned factors were measured by ELISA, whereas bone marrow plasma cell infiltration and Ki-67 expression were estimated immunohistochemically. All measured parameters were higher in pretreated myeloma patients compared to healthy population and were also increasing with the progression of the disease. They all also decreased after effective therapy. Furthermore, all pretreatment values correlated to each other. BAFF seems to be an important growth factor for myeloma plasma cells. Measuring its serum levels, along with the previously mentioned cytokines, may provide important information regarding the degree of myeloma cells’ proliferation. Therefore, they all could be used as markers of proliferation and disease activity.

Prognostic Impact Of Serum Heavy/Light Chain Pairs In Patients With MGUS and Smoldering Myeloma: Long-Term Results From a Single Institution

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 3132-3132
Author(s):  
Carlos Fernández de Larrea ◽  
Laura Magnano ◽  
Montserrat Elena ◽  
María Teresa Cibeira ◽  
Natalia Tovar ◽  
...  
Keyword(s):  
Bone Marrow ◽  
High Risk ◽  
Plasma Cell ◽  
Light Chain ◽  
M Protein ◽  
Cell Infiltration ◽  
Prognostic Impact ◽  
Plasma Cell Infiltration ◽  
Risk Of Progression ◽  
Bone Marrow Plasma

Abstract Background Asymptomatic monoclonal gammopathies, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM), are clinical conditions that usually precede symptomatic multiple myeloma (MM). However, risk stratification is crucial due to the heterogeneous progression rate among patients with these entities, particularly nowadays when chemoprevention trials are encouraged in high risk patients. In this sense, biomarkers and prognostic index based on tumoral load, M-protein behaviour (evolving vs. non-evolving) and/or immunological status have been developed. In MGUS, serum heavy/light chain (HLC) pairs have allowed the identification of abnormal ratios of involved and non-involved immunoglobins for each specific heavy-chain isotype (IgG-kappa/IgG-lambda, IgA-kappa/IgA-lambda and IgM-kappa/IgM-lambda). The aim of the present study was to investigate the prognostic impact on progression of the isotype-specific suppression of the uninvolved HLC-pair in a series of patients with MGUS and SMM with long follow up. Patients and Methods We retrospectively evaluated 114 patients (median age 61 years; 44M/70F) with SMM (35) and MGUS (79). Median follow up for alive patients was 13 years (range 3 to 27 years). Only 12 patients with SMM accomplished both diagnostic criteria for high risk (bone marrow plasma cell infiltration ≥10% and M-protein ≥30 g/L). Heavy isotype distribution was mainly IgG (71%), IgA (15.8%) and IgM (11.4%); only two patients (1.8%; 1 MGUS and 1 SMM) had only light-chain M-protein. Median bone marrow plasma cell infiltration was 4% and 15% in MGUS and SMM, respectively. 13 patients (11.4%) showed an “evolving” pattern of their serum M-protein. All patients had an available initial frozen serum sample. Three serum HLC pairs (IgG, IgM and IgA) were evaluated by immunonephelometry (Hevylite; gently provided by The Binding Site, Ltd); HLC kappa/lambda ratio were calculated for each one. Normal values were obtained from 95% normal values reported in healthy donors. Results Progression to malignant symptomatic gammopathies was observed in 15 patients (13.2%; 9 SMM and 6 MGUS), mainly to MM (13) with exception of AL amyloidosis and Waldenström's macroglobulinemia in one case each. Risk of progression was 4 times higher in patients with SMM than in those with MGUS (p=0.009), being 8 times higher for high risk SMM (p<0.001). An “evolving” pattern of serum M-protein (p=0.004; HR 4.93, IC 95% 1.7 to 14.8) and a serum M-protein greater than 15 g/L (p=0.01; HR 5.2, IC 95% 1.5 to 18.5) were also associated with higher risk of progression. Patients with SMM had lower IgG-lambda, IgA-lambda and HLC IgM ratio (p<0.05) than patients with MGUS. IgG HLC ratio was positively associated with bone marrow plasma cell infiltration (r=0.555; p<0.0001). Normal or lower than normal HLC ratios for IgG and IgM were associated with longer time to progression to symptomatic disease (TTP) than higher values (p=0.008 and p=0.013, respectively) (Figure 1). This difference in HLC IgG ratio were even more evident in SMM patients (p=0.002), where only 1 patient with normal or low HLC IgG ratio has progressed. There was also a trend for HLC IgM ratio in this sense (p=0.08). In a multivariate analysis taking into account SMM vs. MGUS diagnosis, “evolving” pattern and HLC IgM and IgG ratio, only the first three variables remained statistically significant for predicting TTP. Suppression of uninvolved HLC pair was more evident in IgG patients, both MGUS and SMM. Hence, any reduction in IgA-kappa or IgA-lambda isotypes was associated with higher risk of progression (p=0.04) (Figure 2). Conclusion HLC ratios seem to be a valuable tool in the risk stratification of patients with SMM and MGUS. Suppression of the uninvolved isotype (i.e. uninvolved IgA or HLC IgM ratio in IgG MGUS or SMM) is particularly interesting since this phenomenon has not been previously recognized. The picture of differential clonal suppression of heavy-chain isotypes across risk groups is an issue to be prospectively explored. Disclosures: Fernández de Larrea: The Binding Site Ltd: Consultancy, Honoraria.

Bone Marrow Plasma Cell Infiltration in Light-Chain Amyloidosis

2018 ◽  
Vol 18 ◽  
pp. S236
Author(s):  
Luis Gerardo Rodríguez-Lobato ◽  
Natalia Tovar ◽  
Ma. Teresa Cibeira ◽  
Laura Magnano ◽  
Ignacio Isola ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Plasma Cell ◽  
Light Chain ◽  
Cell Infiltration ◽  
Light Chain Amyloidosis ◽  
Plasma Cell Infiltration ◽  
Bone Marrow Plasma

Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma

1992 ◽  
Vol 82 (1) ◽  
pp. 46-49 ◽  
Author(s):  
W. E. Terpstra ◽  
H. M. Lokhorst ◽  
F. Blomjous ◽  
O. J. A. Th. Meuwissen ◽  
A. W. Dekker
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Plasma Cell ◽  
Cell Infiltration ◽  
Bone Marrow Biopsies ◽  
Plasma Cell Infiltration
Sign in / Sign up

Export Citation Format

Share Document